Entific Medical Systems AB acquired by Cochlear Corporation.

On March 4th Cochlear Corporation acquired Entific. The fit between the two companies is perfect in terms of patient base as well as from a technological and a geographical point of view and represents a long term solution where both companies will benefit. By joining forces, the possibilities to broaden and refine the offer will benefit an increasing number of people.

Entific is known for its Baha® bone conduction implant that treats conductive and mixed hearing losses and Single Sided Deafness ™, whereas Cochlear’s cochlear implant range, Nucleus®, is designed to treat bilateral profound sensorineural hearing loss. The two companies therefore complement each other’s offers, without any unnecessary competition.

>From a technological standpoint there are many synergies and it will be beneficial for both parties to share experience in both implant technology and in sound processing. These joint efforts will allow for continued strong development and the possibilities arising from the combination of technological know how will ensure long term product innovation.

The geographical coverage of the two companies should also improve throughout the world. Although Cochlear Corporation has a larger world presence, Entific is in many markets reaching out to a larger number of clinics. The combined efforts will therefore strengthen the global presence and help to bring the appropriate treatment closer to patients.

“I have a lot of respect for Cochlear’s technological base and achievements and feel that Entific’s people and products are joining a likeminded environment. This should benefit patients, clinicians and employees alike,” says Entific’s CEO Dan Pitulia.